For common outcomes there was similar efficacy between PDE-5 inhibitors
Background There are no r and omised and properly blinded trials directly comparing one PDE-5 inhibitor with another in a normal home setting .
Valid indirect comparisons with a common comparator must examine equivalent doses , similar duration , similar population s , with the same outcomes reported in the same way .
Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease.
This was a double-blind , placebo-controlled , flexible-dose study of the efficacy and safety of sildenafil in men with erectile dysfunction ( ED ) and clinical ly stable coronary artery disease ( CAD ) . Patients were r and omized to receive sildenafil or placebo for 12 weeks . Primary outcomes were questions 3 and 4 of the International Index of Erectile Function ( IIEF ) . Secondary outcomes included the other IIEF questions and functional domains , the Life Satisfaction Checklist , the Erectile Dysfunction Inventory of Treatment Satisfaction , 2 global efficacy assessment questions , and intercourse success rate . By week 12 , sildenafil-treated patients ( n = 70 ) showed significant improvements on questions 3 and 4 compared with placebo-treated patients ( n = 72 ; p < 0.01 ) . Larger percentages of sildenafil-treated patients reported improved erections ( 64 % ) and improved intercourse ( 65 % ) compared with placebo-treated patients ( 21 % and 19 % , respectively ) . Sildenafil-treated patients were highly satisfied with treatment and their sexual life compared with placebo-treated patients . Forty-seven percent of sildenafil- and 32 % of placebo-treated patients experienced adverse events , including transient headache , hypertension , flushing , and dyspepsia . There were no serious drug-related cardiovascular effects . Thus , sildenafil is an effective and well-tolerated treatment for ED in men with CAD . Sildenafil was not associated with additional safety risks in this patient population
For common outcomes there was similar efficacy between PDE-5 inhibitors
Background There are no r and omised and properly blinded trials directly comparing one PDE-5 inhibitor with another in a normal home setting .
Valid indirect comparisons with a common comparator must examine equivalent doses , similar duration , similar population s , with the same outcomes reported in the same way .